San Diego, CA (PRWEB) December 22, 2014
Stemiotics, Inc., a supplier of stem cell generation services, today announced it has licensed key intellectual property pertaining to the application of modified RNA from CELLSCRIPT, LLC of Madison, WI. CELLSCRIPT holds an exclusive license to a portfolio of issued and pending patents based on discoveries made at the University of Pennsylvania covering the use of synthetic messenger RNA (mRNA) containing modified nucleotides to evade antiviral responses in mammalian cells. This breakthrough technology has opened new vistas for the application of mRNA as a gene expression vector in human therapeutics and cell fate manipulation. The license to Stemiotics is for use of modified RNA in the production of human induced pluripotent stem cells (iPSCs) for research applications such as disease modeling and drug discovery.
Stemiotics is already using CELLSCRIPT's ultra-low immunogenicity mRNA to reprogram human skin cells into pluripotent stem cells with the potential to become any cell type in the body. In addition to the incorporation of modified nucleotides, CELLSCRIPT's advanced synthetic mRNA is subject to novel purification techniques that virtually eliminate residual innate immune responses to the mRNA on delivery into human or animal cells in vivo or in culture. Stemiotics is committed to applying clinically relevant, state-of-the-art technology in its iPSC derivation pipeline. The company uses only xeno-free reagents at all steps of the process, from the initial expansion of the donor skin cells to the cryogenic preservation of the artificially-induced pluripotent stem cells. Stemiotics employs the most potent cocktail of cellular reprogramming factors currently available, including engineered transcription factors based on IP which has been exclusively licensed to CELLSCRIPT. This sophisticated technology allows Stemiotics to convert human skin cells into pluripotent stem cells in just over a week in feeder-free conditions and without the need for drug-like small molecule accelerants.
Stemiotics believes that the mRNA-based reprogramming system it has developed is the fastest, most productive and safest approach to converting human skin cells into pluripotent stem cells yet devised. The company offers high-throughput iPSC derivation on a fee-for-service basis with fast turnaround times and at a cost of only $1000 per line, an order of magnitude below prevailing industry norms. The licensing relationship with CELLSCRIPT will further enhance Stemiotics position as an emerging leader in the field of cellular reprogramming, with all its great promise for advancing the understanding of disease, the development of new drugs and, ultimately, for cell-based therapies and regenerative medicine.
Continued here:
Stemiotics Licenses Modified RNA for Cell Reprogramming
